➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Mallinckrodt
Johnson and Johnson
Baxter
Merck

Last Updated: January 21, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Dactolisib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Dactolisib?

Dactolisib is an investigational drug.

There have been 4 clinical trials for Dactolisib. The most recent clinical trial was a Phase 3 trial, which was initiated on October 21st 2019.

The most common disease conditions in clinical trials are Respiratory Tract Infections and [disabled in preview]. The leading clinical trial sponsors are Restorbio Inc., National Institute on Aging (NIA), and [disabled in preview].

There are one hundred and thirty-three US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Dactolisib
TitleSponsorPhase
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older AdultsNational Institute on Aging (NIA)Phase 2
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older AdultsRestorbio Inc.Phase 2
Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing HomesRestorbio Inc.Phase 3

See all Dactolisib clinical trials

Clinical Trial Summary for Dactolisib

Top disease conditions for Dactolisib
Top clinical trial sponsors for Dactolisib

See all Dactolisib clinical trials

US Patents for Dactolisib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dactolisib   Start Trial Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Start Trial
Dactolisib   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
Dactolisib   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
Dactolisib   Start Trial Triazine compounds as PI3 kinase and mTOR inhibitors Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dactolisib

Drugname Country Document Number Estimated Expiration Related US Patent
Dactolisib Australia AU2015244171 2034-04-11   Start Trial
Dactolisib Australia AU2015244179 2034-04-11   Start Trial
Dactolisib Canada CA2945128 2034-04-11   Start Trial
Dactolisib Canada CA2945129 2034-04-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Mallinckrodt
Johnson and Johnson
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.